This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Medical Info Systems Stocks to Gain From Healthcare Digitization
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, 10x Genomics and Omnicell are expected to gain from the GenAI wave.
10x Genomics (TXG) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
10x Genomics (TXG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
American Well Corporation (AMWL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
American Well (AMWL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Oct 11, 2024
by Zacks Equity Research
Companies in The News Are: DAL,DPZ,NEOG,TXG
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 31.91% and 1.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q2 Potential of 10x Genomics (TXG): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Azenta (AZTA) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 128.57% and 4.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 33.70% and 1.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GE HealthCare Technologies (GEHC) Tops Q2 Earnings Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 2.04% and 1.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Fulgent Genetics (FLGT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Does 10x Genomics (TXG) Have the Potential to Rally 85.65% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 85.7% upside potential for 10x Genomics (TXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
10x Genomics (TXG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
International Markets and 10x Genomics (TXG): A Deep Dive for Investors
by Zacks Equity Research
Review 10x Genomics' (TXG) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
by Zacks Equity Research
10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
3 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
Down -23.92% in 4 Weeks, Here's Why 10x Genomics (TXG) Looks Ripe for a Turnaround
by Zacks Equity Research
10x Genomics (TXG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -13.89% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.